Compare CACC & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CACC | WGS |
|---|---|---|
| Founded | 1972 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.6B |
| IPO Year | 1992 | N/A |
| Metric | CACC | WGS |
|---|---|---|
| Price | $475.59 | $135.73 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $465.00 | $138.13 |
| AVG Volume (30 Days) | 124.0K | ★ 378.7K |
| Earning Date | 01-29-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 151.44 | N/A |
| EPS | ★ 37.89 | 0.07 |
| Revenue | ★ $1,232,900,000.00 | $402,190,000.00 |
| Revenue This Year | $129.15 | $41.17 |
| Revenue Next Year | $1.97 | $23.53 |
| P/E Ratio | ★ $12.57 | $1,878.59 |
| Revenue Growth | 45.72 | ★ 50.50 |
| 52 Week Low | $401.90 | $55.17 |
| 52 Week High | $560.00 | $170.87 |
| Indicator | CACC | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 60.60 | 44.44 |
| Support Level | $450.53 | $124.26 |
| Resistance Level | $483.72 | $138.73 |
| Average True Range (ATR) | 13.34 | 5.71 |
| MACD | 1.52 | 0.06 |
| Stochastic Oscillator | 83.61 | 55.87 |
Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.